The trial aims to investigate the tolerability and safety of intratumoral injections of ZIN ATI-001 (Ad-RTS-IL-12 or INXN-2001).
Mary Crowley Medical Research Center executive medical director John Nemunaitis said ZIN ATI-001 demonstrates the ability to engineer complex, controllable transgenes whose properties cannot be reproduced through traditional therapeutic approaches.